BUZZ-Immunovaccine Inc: Ebola vaccine technology succeeds

Mon Aug 25, 2014 12:00pm EDT
Email This Article |
Share This Article
  • Facebook
  • LinkedIn
  • Twitter
| Print This Article
[-] Text [+]

** Clinical-stage vaccine developer's shares up 25.8 pct at C$1.22 on the Toronto Venture Exchange

** Announces positive results for a vaccine formulated using its DepoVax technology in an Ebola virus challenge study

** All vaccinated cynomolgus monkeys survived the exposure to a lethal dose of the wild type Zaire strain of Ebola virus, believed to be the most lethal, in a preliminary study

** Up to Friday's close, Immunovaccine's stock had more than doubled this year